Dulaglutide and Levothyroxine interaction

Dulaglutide and Levothyroxine: both prescribing labels flag this combination with the strongest language, such as a contraindication, a boxed warning, or an instruction to avoid it.

Major

Do not combine without a prescriber's guidance. The label language below is the strongest FDA uses.

What the FDA labels say

From the Dulaglutide (Trulicity) label · effective 2026-06-16

Major

WARNING: RISK OF THYROID C-CELL TUMORS In male and female rats, dulaglutide causes a dose-related and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) after lifetime exposure.

Boxed warningby drug classView label on DailyMed
Major

It is unknown whether TRULICITY causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of dulaglutide-induced rodent thyroid C-cell tumors has not been determined [see Warnings and Precautions ( 5.1 ), and Nonclinical Toxicology ( 13.1 )] .

Boxed warningby drug classView label on DailyMed
Major

Counsel patients regarding the potential risk of MTC with use of TRULICITY and inform them of symptoms of thyroid tumors (e.g., mass in the neck, dysphagia, dyspnea, persistent hoarseness).

Boxed warningby drug classView label on DailyMed
Major

Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with TRULICITY [see Contraindications ( 4 ) and Warnings and Precautions ( 5.1 )] .

Boxed warningby drug classView label on DailyMed
Major

WARNING: RISK OF THYROID C-CELL TUMORS See full prescribing information for complete boxed warning.

Boxed warningby drug classView label on DailyMed

From the Levothyroxine (Levothyroxine Sodium) label · effective 2024-07-10

Moderate

Worsening of Diabetic Control : May worsen glycemic control and result in increased antidiabetic agent or insulin requirements.

Warnings and precautionsby drug classView label on DailyMed
Moderate

Worsening of Diabetic Control Addition of levothyroxine therapy in patients with diabetes mellitus may worsen glycemic control and result in increased antidiabetic agent or insulin requirements.

Warnings and precautionsby drug classView label on DailyMed
Moderate

Antidiabetic Therapy Addition of levothyroxine to antidiabetic or insulin therapy may result in increased antidiabetic agent or insulin requirements.

Drug interactionsby drug classView label on DailyMed

Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.

Open in the checker

Not medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.